Last reviewed · How we verify
NCT03062124
SpyGlass in Preoperative Diagnostics of Presumed Main Duct IPMNs: Efficacy and Novel Insights on Complications
trial testing SpyGlass pancreatoscopy in Intraductal Papillary Mucinous Neoplasm in 101 participants. Completed in 31 December 2020.
31 December 2020
Quick facts
| Lead sponsor | Helsinki University Central Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 101 |
| Start date | 18 November 2017 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 3 locations across Sweden, Finland |
Drugs / interventions tested
- SpyGlass pancreatoscopy
Conditions studied
- Intraductal Papillary Mucinous Neoplasm — all drugs for Intraductal Papillary Mucinous Neoplasm →
Sponsor
Helsinki University Central Hospital
Who can join
18 and older, any sex, with Intraductal Papillary Mucinous Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Distinguishing intraductal papillary mucinous neoplasms (IPMNs) from other pancreatic cystic lesions is essential as IPMNs bear risk of becoming malignant. Differentiating the main pancreatic duct involving IPMNs (MD-IPMNs) with imaging can be difficult. Single-operator peroral pancreatoscopy (SOPP) has shown to be a promising method offering additional information on suspected lesions in the main pancreatic duct (MD). We aimed to establish the role of SOPP in preoperative diagnostics of presumed MD-IPMNs. A secondary objective was to identify factors that contribute to SOPP-related complications.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The role of pancreatoscopy in the diagnostic work-up of intraductal papillary mucinous neoplasms: a systematic review and meta-analysis.
de Jong DM, Stassen PMC, Groot Koerkamp B, Ellrichmann M, et al · · 2023 · cited 23× · PMID 35668651 · DOI 10.1055/a-1869-0180 -
Single-operator peroral pancreatoscopy in the preoperative diagnostics of suspected main duct intraductal papillary mucinous neoplasms: efficacy and novel insights on complications.
Vehviläinen S, Fagerström N, Valente R, Seppänen H, et al · · 2022 · cited 10× · PMID 35277769 · DOI 10.1007/s00464-022-09156-3
Verify or expand the search:
- PubMed search for NCT03062124
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Intraductal Papillary Mucinous Neoplasm
Currently open trials in the same condition.
- NCT07117045 — Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer · recruiting
- NCT06638866 — AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort · recruiting
- NCT05433935 — Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas · recruiting
- NCT04291651 — UCSF PANC Cyst Registry · recruiting
Other Helsinki University Central Hospital trials
Trials by the same sponsor.
- NCT07423637 — The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectivene · NA · not yet recruiting
- NCT07462559 — KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study · Phase 1 · not yet recruiting
- NCT07458984 — FMT Capsules for rCDI · Phase 3 · not yet recruiting
- NCT07001423 — ChOlecystectomy aFter successFul Endoscopic Common Bile Duct Stone Extraction in Elderly · NA · recruiting
- NCT07155629 — Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03062124 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Helsinki University Central Hospital
- Last refreshed: 20 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03062124.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing